Literature DB >> 6423278

Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.

A P Chahinian, L Norton, J F Holland, L Szrajer, R D Hart.   

Abstract

Little information is available regarding the effectiveness of chemotherapeutic agents in malignant mesothelioma. Human malignant mesothelioma specimens from two patients were successfully transplanted and maintained in homozygous nude mice. Screening of chemotherapeutic agents revealed that cisplatin was the most active single agent in one line, and mitomycin C in the other. The combination of mitomycin C and cisplatin, however, was the most effective regimen for both lines of xenografted human mesothelioma. Based on these results in nude mice, a clinical trial of mitomycin C and cisplatin was undertaken. Four of 12 patients showed objective response (one complete and three partial). These clinical results support the usefulness of the nude mouse model for malignant mesothelioma.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6423278

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Update in cancer chemotherapy, Part IV. Lung cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-11       Impact factor: 1.798

3.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Authors:  J M Onoda; K K Nelson; S M Pilarski; N S White; R G Mihu; K V Honn
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

5.  Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.

Authors:  D A Amato; E C Borden; M Shiraki; H T Enterline; C Rosenbaum; H L Davis; A R Paul; C M Stevens; H J Lerner
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice.

Authors:  T Ohnuma; L Szrajer; J F Holland; M Kurimoto; J Minowada
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases.

Authors:  Y Saikawa; T Kubota; T Furukawa; K Kumai; K Yoshino; K Ishibiki; M Kitajima
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Authors:  Emma M Rath; Yuen Yee Cheng; Mark Pinese; Kadir H Sarun; Amanda L Hudson; Christopher Weir; Yiwei D Wang; Anders P Håkansson; Viive M Howell; Guo Jun Liu; Glen Reid; Robert B Knott; Anthony P Duff; W Bret Church
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

9.  Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Authors:  Claudia Baron; Marie Buchholz; Britta Majchrzak-Stiller; Ilka Peters; Daniel Fein; Thomas Müller; Waldemar Uhl; Philipp Höhn; Johanna Strotmann; Chris Braumann
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.